Jazmine N. Brown

FDA investigator

Appears on 14 documents from 2022 to 2025, most often at sites in Pennsylvania. Most often cites control of microbiological contamination (21 CFR 211.113).

14
Documents on file
6.6
Observations per 483
2022
First seen
2025
Most recent

What they cite most

From 93 observations

Activity by year

2022: 2, 2023: 3, 2024: 7, 2025: 2

Where

Pennsylvania 5 · Connecticut 2 · Maryland 2 · New York 2 · Texas 2 · Montana 1

Is Jazmine N. Brown coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

14 documents, newest first
FirmOpen
483 Wells Pharma of Houston LLCMar 28, 2025 · Houston, Texas
483 Revive Rx LLC dba Revive Rx PharmacyFeb 7, 2025 · Houston, Texas
483 SCA Pharmaceuticals, LLCDec 20, 2024 · Windsor, Connecticut
483 OSRX Inc.Oct 25, 2024 · Missoula, Montana
483 Pine Pharmaceuticals, LLCSep 30, 2024 · Tonawanda, New York
483 ProRx LLCAug 2, 2024 · Exton, Pennsylvania
483 AstraZeneca Pharmaceuticals LPMay 31, 2024 · Gaithersburg, Maryland

About this profile

What does Jazmine N. Brown inspect?

Jazmine N. Brown appears on 14 documents on file covering 13 sites, most often in Pennsylvania.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.42 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Jazmine N. Brown is dated Mar 28, 2025.